ConductScience.org, home

Comparison · NCT03471767-956cfb6a

AXS-05 vs Bupropion SR: Change in Smoking Behavior

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. AXS-05 vs Bupropion SR: Change in Smoking Behavior. Trial comparisons, record NCT03471767-956cfb6a. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03471767-956cfb6a

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.6670.4670.82wilson
Risk in group 20.6670.4370.837wilson
Risk difference, group 1 minus group 20-0.2630.276newcombe hybrid score
Risk ratio, group 1 over group 210.6491.54log
Odds ratio, group 1 over group 210.2743.66log
Number needed to treatfrom the risk difference intervalthe two groups' risks are equal

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1AXS-05AXS-05: Dextromethorphan Immediate Release + Bupropion Sustained Release: Take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal for 4 weeks.1624OG000
Group 2Bupropion SRBupropion SR: Bupropion Sustained Release: Take 1 tablet two times per day, at least 8 hours apart and 1 hour prior to a meal, and 2 hours after a meal for 4 weeks1218OG001

Outcome

Type
SECONDARY
Title
Change in Smoking Behavior
Description
7-day point prevalence smoking abstinence. Measured by composite self-report diaries and biochemically confirmed via expired CO and salivary cotinine.
Time frame
3-Week Follow-Up Visit (V4), 4-Week Follow-Up Visit (V5)
Population
Not all participants participated in this abstinence test.

Source ClinicalTrials.gov

Trial

Title
AXS-05 Phase II Trial on Smoking Behavior
NCT number
NCT03471767
Phases
PHASE2
Conditions
Smoking Cessation, Smoking, Cigarette, Nicotine Dependence
Interventions
AXS-05, Bupropion SR
Lead sponsor
James Davis
Results first posted
2022-10-12

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03471767-956cfb6a